Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
BMJ Open. 2019 Sep 3;9(9):e031080. doi: 10.1136/bmjopen-2019-031080.
Multimorbidity and polypharmacy are major risk factors for potentially inappropriate prescribing (eg, overprescribing and underprescribing), and systematic medication reviews are complex and time consuming. In this trial, the investigators aim to determine if a systematic software-based medication review improves medication appropriateness more than standard care in older, multimorbid patients with polypharmacy.
Optimising PharmacoTherapy In the multimorbid elderly in primary CAre is a cluster randomised controlled trial that will include outpatients from the Swiss primary care setting, aged ≥65 years with ≥three chronic medical conditions and concurrent use of ≥five chronic medications. Patients treated by the same general practitioner (GP) constitute a cluster, and clusters are randomised 1:1 to either a standard care sham intervention, in which the GP discusses with the patient if the medication list is complete, or a systematic medication review intervention based on the use of the 'Systematic Tool to Reduce Inappropriate Prescribing'-Assistant (STRIPA). STRIPA is a web-based clinical decision support system that helps customise medication reviews. It is based on the validated 'Screening Tool of Older Person's Prescriptions' (STOPP) and 'Screening Tool to Alert doctors to Right Treatment' (START) criteria to detect potentially inappropriate prescribing. The trial's follow-up period is 12 months. Outcomes will be assessed at baseline, 6 and 12 months. The primary endpoint is medication appropriateness, as measured jointly by the change in the Medication Appropriateness Index (MAI) and Assessment of Underutilisation (AOU). Secondary endpoints include the degree of polypharmacy, overprescribing and underprescribing, the number of falls and fractures, quality of life, the amount of formal and informal care received by patients, survival, patients' quality adjusted life years, patients' medical costs, cost-effectiveness of the intervention, percentage of recommendations accepted by GPs, percentage of recommendation rejected by GPs and patients' willingness to have medications deprescribed.
The ethics committee of the canton of Bern in Switzerland approved the trial protocol. The results of this trial will be published in a peer-reviewed journal.
Swiss National Science Foundation, National Research Programme (NRP 74) 'Smarter Healthcare'.
Clinicaltrials.gov (NCT03724539), KOFAM (Swiss national portal) (SNCTP000003060), Universal Trial Number (U1111-1226-8013).
多病共存和多种药物治疗是潜在不适当处方(例如,过度处方和处方不足)的主要危险因素,系统药物审查既复杂又耗时。在这项试验中,研究人员旨在确定基于系统软件的药物审查是否比多病共存且多种药物治疗的老年患者的标准护理更能提高药物的适当性。
优化老年人的药物治疗是一项整群随机对照试验,将包括来自瑞士初级保健环境的门诊患者,年龄≥65 岁,患有≥三种慢性疾病且同时使用≥五种慢性药物。由同一名全科医生(GP)治疗的患者构成一个群组,群组按 1:1 随机分配到标准护理假干预组或基于使用“减少不适当处方的系统工具-助理”(STRIPA)的系统药物审查干预组。STRIPA 是一个基于网络的临床决策支持系统,有助于定制药物审查。它基于经过验证的“老年人处方筛选工具”(STOPP)和“提醒医生正确治疗的筛选工具”(START)标准来检测潜在的不适当处方。试验的随访期为 12 个月。结果将在基线、6 个月和 12 个月时进行评估。主要终点是药物适当性,通过药物适宜指数(MAI)和未充分利用评估(AOU)的变化联合测量。次要终点包括药物过度治疗和药物不足的程度、跌倒和骨折的数量、生活质量、患者接受的正式和非正式护理的数量、生存、患者的质量调整生命年、患者的医疗费用、干预措施的成本效益、GP 接受建议的百分比、GP 和患者拒绝建议的百分比以及患者愿意减少药物剂量的意愿。
瑞士伯尔尼州的伦理委员会批准了试验方案。这项试验的结果将在同行评议的期刊上发表。
瑞士国家科学基金会,国家研究计划(NRP 74)“更智能的医疗保健”。
Clinicaltrials.gov(NCT03724539)、KOFAM(瑞士国家门户)(SNCTP000003060)、通用试验编号(U1111-1226-8013)。